title: Efficacy of re-treatment by peginterferon alpha-2a and ribavirin in a child with hepatitis C.
abstract: BACKGROUND
  There is currently no consensus treatment for children non-responsive to peginterferon (Peg-IFN) and ribavirin.
  
  
  METHODS
  Here, we present a Japanese child with chronic hepatitis C with fibrosis, who did not respond to Peg-IFN α-2b but responded to Peg-IFN α-2a with ribavirin, accompanied with fluvastatin. To date, there has been no reported case of re-treatment in children. The early viral response occurred soon after starting treatment using Peg-IFN α-2a/ribavirin plus fluvastatin.
  
  
  CONCLUSIONS
  Our result indicates that when treatment by Peg-IFN α-2b/ribavirin combination therapy is not efficient, combination therapy using Peg-IFN α-2a/ribavirin plus fluvastatin should be considered in children with advanced liver change.
authors.affiliation: Department of Pediatrics, Tokyo Medical University, Japan.
authors.forename: Shigeo
authors.initials: S
authors.lastname: Nishimata
authors.affiliation: Department of Pediatrics, Tokyo Medical University, Japan.
authors.forename: Norito
authors.initials: N
authors.lastname: Tsutsumi
authors.affiliation: Department of Pediatrics, Tokyo Medical University, Japan.
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Suzuki
authors.affiliation: Department of Pediatrics, Tokyo Medical University, Japan.
authors.forename: Ryuhei
authors.initials: R
authors.lastname: Nagao
authors.affiliation: Department of Pediatrics, Tokyo Medical University, Japan.
authors.forename: Yasuyo
authors.initials: Y
authors.lastname: Kashiwagi
authors.affiliation: Department of Pediatrics, Tokyo Medical University, Japan. Electronic address: hisashi@tokyo-med.ac.jp.
authors.forename: Hisashi
authors.initials: H
authors.lastname: Kawashima
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D002648:Child; D004359:Drug Therapy, Combination / Q000379:methods; D005229:Fatty Acids, Monounsaturated / Q000627:therapeutic use; D000077340:Fluvastatin; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D005229:Fatty Acids, Monounsaturated; D007211:Indoles; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; D000077340:Fluvastatin; C417083:peginterferon alfa-2b
keywords: Fluvastatin; Non-responsive; Peginterferon; Ribavirin; Sustained virologic response